Glaukos (NYSE:GKOS) Price Target Raised to $225.00

Glaukos (NYSE:GKOS) had its target price raised by Stifel Nicolaus from $190.00 to $225.00 in a research report released on Thursday morning, MarketBeat reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

GKOS has been the topic of a number of other reports. Mizuho set a $225.00 price target on shares of Glaukos in a research report on Thursday. Wells Fargo & Company boosted their price objective on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. UBS Group started coverage on shares of Glaukos in a report on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 price objective for the company. Needham & Company LLC increased their target price on shares of Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $240.00 target price (up from $195.00) on shares of Glaukos in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and an average target price of $216.71.

Glaukos Stock Down 2.3%

GKOS stock opened at $236.92 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.46. The stock has a market capitalization of $14.03 billion, a price-to-earnings ratio of -80.58 and a beta of 0.69. The business’s fifty day moving average price is $173.30 and its two-hundred day moving average price is $141.14. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $248.75.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The company had revenue of $211.03 million during the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company’s revenue was up 58.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) earnings per share. On average, equities analysts anticipate that Glaukos will post 0.15 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gilbert H. Kliman sold 2,500 shares of Glaukos stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the sale, the director directly owned 37,406 shares in the company, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 82,500 shares of company stock worth $14,862,000 over the last quarter. Corporate insiders own 5.90% of the company’s stock.

Institutional Trading of Glaukos

Several hedge funds and other institutional investors have recently made changes to their positions in GKOS. State of Wyoming increased its stake in shares of Glaukos by 6.8% in the third quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock valued at $169,000 after buying an additional 66 shares during the period. Wealth Alliance LLC raised its holdings in Glaukos by 4.5% in the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after buying an additional 98 shares during the last quarter. Abel Hall LLC raised its holdings in Glaukos by 3.5% in the 3rd quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier’s stock valued at $531,000 after buying an additional 108 shares during the last quarter. Choreo LLC boosted its position in Glaukos by 4.0% during the 3rd quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $582,000 after buying an additional 136 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in Glaukos by 25.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 138 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported third-quarter revenue of approximately $211 million, up 58% year over year and well above the $168 million analyst consensus. Earnings were $0.47 per share versus expectations for a $0.10–$0.12 loss and a $0.16 loss in the prior-year quarter. Glaukos Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management raised fiscal 2026 revenue guidance to $775 million–$785 million, substantially above the roughly $691.5 million consensus estimate. It also set a preliminary fiscal 2027 sales target of $1 billion, versus Wall Street expectations of about $849 million, reinforcing the growth story. Glaukos sets $1 billion 2027 sales goal
• Positive Sentiment: Analyst sentiment improved following the results. Zacks Research upgraded GKOS from “hold” to “strong buy,” while Needham raised its price target to $251 and JPMorgan lifted its target to $240, maintaining an “overweight” rating.
• Neutral Sentiment: Other firms also raised their targets, including Wells Fargo to $226, BTIG to $234 and Stifel to $225. However, each remains below the recent trading level, suggesting analysts are becoming more constructive while still seeing limited near-term upside at the current valuation.
• Negative Sentiment: The headline profit included factors that may not fully reflect recurring operating earnings. Glaukos continues to report a negative net margin, and commentary noted that underlying profitability is thinner than adjusted figures suggest. With a price-to-earnings ratio based on losses and the stock near its 52-week high, expectations and valuation remain elevated.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.